In the recent updates from the biotech market, multiple events involving
Edwards Lifesciences Corp stand out. The prominent biotech company have been displaying a significant performance with its
stock outperforming competitors on several occasions despite underperforming at times in comparison to other competitors. Notably,
Becton Dickinson acquired the critical care unit from Edwards Lifesciences for a whopping $4.2 billion. This event resulted in a surprising jump in Edwards Lifesciences' stock. Analysts have been increasing their price targets post this report, given the robust Q4 and full-year 2023 financial results displayed by the company. Furthermore,
Vestal Point Capital LP and Rafferty Asset Management LLC bought significant shares of the company, indicating the company's strong market position. Edwards Lifesciences has also unexpectedly announced its plan to spin-off its critical care unit in 2024. Despite facing an EU antitrust complaint by Meril, Edwards Lifesciences' sales view for 2024 has gone up after beating the Q1 earnings' expectation.
Edwards Lifesciences Corp EW News Analytics from Wed, 26 Jul 2023 07:00:00 GMT to Sun, 09 Jun 2024 13:36:56 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -3
